Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2014-08-21 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2014年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '昆明制药集团股份有限公司 2014 年半年度报告', which translates to 'Kunming Pharmaceutical Group Co., Ltd. 2014 Semi-Annual Report'. It contains detailed financial data for the first half of 2014, including income, profit, cash flow, and asset information. It also includes management discussion and analysis, business segment performance, investment status, and fundraising usage. The document is comprehensive and covers a period shorter than a full fiscal year (half-year). It is not a brief announcement or a certification letter but a full financial report with substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2014
2014-08-21 Chinese
七届十二次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board of Kunming Pharmaceutical Group Co., Ltd. regarding the approval of the company's 2014 half-year (semi-annual) report and a special report on the use of raised funds. It includes the supervisory board's audit opinion on the 2014 half-year report, confirming compliance with relevant laws, regulations, and stock exchange requirements. The document is relatively short (864 characters) and primarily serves as an announcement of the supervisory board's resolution and opinion on the half-year report rather than the report itself. Therefore, it is not the full Interim/Quarterly Report (IR) but an announcement related to it. Given the nature and length, it fits best under Regulatory Filings (RNS) as a formal disclosure of supervisory board resolutions and audit opinions on interim reports, rather than the full report itself or a report publication announcement.
2014-08-21 Chinese
2014年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2014 年半年度报告摘要" which translates to "2014 Semi-Annual Report Summary." It contains detailed financial data for the half-year period, including main financial data, shareholder changes, management discussion and analysis, business segment analysis, investment status, and subsidiary information. The document includes actual financial figures such as total assets, net profit, cash flow, revenue, and expenses for the reporting period. It also discusses operational activities, risks, and future plans. The length of the document is substantial (15,000 characters), and it is not merely an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. H1 2014
2014-08-21 Chinese
七届二十三次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details a decision made by the company's board of directors regarding the establishment of a subsidiary by a wholly-owned subsidiary. The document includes voting results and confirms compliance with company law and articles of association. It is not a full report, financial statement, or regulatory filing but an announcement of a board decision. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on board decisions, not financial results or other report types.
2014-08-04 Chinese
关于2013年授予股权激励所涉限制性股票第一次解锁的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the first unlocking of restricted shares granted under the 2013 equity incentive plan. It details the number of shares unlocked, the conditions for unlocking, the approval and implementation of the equity incentive plan, and the resulting changes in shareholding. The document includes legal opinions and confirmations that the unlocking conditions have been met. It is a formal announcement about a specific corporate action related to equity incentive shares unlocking, not a full financial report or earnings release. It does not contain financial statements or comprehensive financial data, nor is it a regulatory filing or certification. The content fits best under a category related to share transactions or capital changes due to equity incentive plans. The closest specific category is "Transaction in Own Shares (POS)" since it involves unlocking and releasing restricted shares previously granted to employees, which affects share circulation and capital structure. Therefore, the document is classified as POS with high confidence.
2014-07-18 Chinese
七届二十二次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of Kunming Pharmaceutical Group Co., Ltd. regarding the resolution passed in the 22nd meeting of the 7th board. The content focuses on the approval of the unlocking of restricted stock incentives granted in 2013, detailing the conditions and criteria for unlocking these stocks. It is a board resolution announcement related to stock incentive plans and does not contain financial statements or detailed financial performance data. It is not an annual report, interim report, or earnings release. It is also not a regulatory filing or certification. The document is specifically about a board decision, which fits the category of Board/Management Information (MANG). The document length is short (1579 characters), and it is not merely announcing the publication of a report but is itself the announcement of a board resolution.
2014-07-18 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.